Table 4 Cox regression analysis of OS

Univariable analysis

 Tumor PLK4 IHC score

  >0 vs. ≤0

0.333

2.082 (0.472-9.194)

  >3 vs. ≤3

0.018

3.924 (1.259-12.228)

  >6 vs. ≤6

0.010

3.619 (1.357-9.650)

Age, ≥60 years vs. <60 years

0.019

3.891 (1.249-12.120)

Menopausal status, post-menopause vs. pre-menopause

0.246

2.407 (0.546-10.600)

Diabetes, yes vs. no

0.315

1.722 (0.597-4.964)

Hypertension, yes vs. no

0.144

2.082 (0.779-5.566)

Histological subtype

 Endometrioid carcinoma G1/G2 (reference)

1.000

 Endometrioid carcinoma G3 vs. endometrioid carcinoma G1/G2

0.001

8.753 (2.325-32.952)

 Serous endometrial carcinoma vs. endometrioid carcinoma G1/G2

0.082

3.585 (0.850-15.117)

 Clear cell endometrial carcinoma vs. endometrioid carcinoma G1/G2

<0.001

17.499 (4.372-70.042)

Myometrial invasion ≥50%, yes vs. no

0.092

2.389 (0.867-6.586)

Cervical invasion, stromal vs. none or epithelia

0.014

3.452 (1.281-9.303)

Lymphovascular invasion, yes vs. no

0.024

3.136 (1.166-8.438)

Higher FIGO stage

0.005

1.822 (1.200-2.765)

CA125 abnormity, yes vs. no

0.530

1.374 (0.509-3.708)

CA19-9 abnormity, yes vs. no

0.756

1.185 (0.407-3.448)

CEA abnormity, yes vs. no

0.450

1.461 (0.547-3.904)

Adjuvant radiotherapy, yes vs. no

0.165

2.868 (0.649-12.671)

Adjuvant chemotherapy, yes vs. no

0.101

2.293 (0.852-6.171)

Multivariable analysis

 Tumor PLK4 IHC score, >3 vs. ≤3

0.026

3.918 (1.180-13.010)

 Hypertension, yes vs. no

0.047

3.108 (1.013-9.529)

Histological subtype

 Endometrioid carcinoma G1/G2 (reference)

1.000

 Endometrioid carcinoma G3 vs. endometrioid carcinoma G1/G2

<0.001

19.661 (4.213-91.746)

 Serous endometrial carcinoma vs. endometrioid carcinoma G1/G2

0.792

1.241 (0.248-6.207)

 Clear cell endometrial carcinoma vs. endometrioid carcinoma G1/G2

<0.001

30.569 (6.359-146.950)

Higher FIGO stage

0.001

2.413 (1.438-4.049)